77 related articles for article (PubMed ID: 20082492)
1. A prostate cancer 'vaccine' under development.
Mayo Clin Health Lett; 2009 Dec; 27(12):4. PubMed ID: 20082492
[No Abstract] [Full Text] [Related]
2. Cancer vaccine approval could open floodgates.
Nat Med; 2010 Jun; 16(6):615. PubMed ID: 20526296
[No Abstract] [Full Text] [Related]
3. The regulator disapproves.
Nat Biotechnol; 2008 Jan; 26(1):1. PubMed ID: 18182998
[No Abstract] [Full Text] [Related]
4. Consultation corner. Prostate cancer vaccine offers new direction.
Drake C
Johns Hopkins Med Lett Health After 50; 2010 Sep; 22(7):6-7. PubMed ID: 20848753
[No Abstract] [Full Text] [Related]
5. Fallout from flip-flops.
Froese P
Nat Biotechnol; 2008 Jun; 26(6):614-5. PubMed ID: 18536677
[No Abstract] [Full Text] [Related]
6. Death threats for discrepancies over treatment data.
Burton A
Lancet Oncol; 2007 Jul; 8(7):577. PubMed ID: 17668482
[No Abstract] [Full Text] [Related]
7. Concerns about Provenge simmer as CMS ponders coverage.
Goozner M
J Natl Cancer Inst; 2011 Feb; 103(4):288-9. PubMed ID: 21303996
[No Abstract] [Full Text] [Related]
8. The Provenge decision.
DeVita VT
Nat Clin Pract Oncol; 2007 Jul; 4(7):381. PubMed ID: 17554239
[No Abstract] [Full Text] [Related]
9. Cellular immunotherapy licensed for advanced prostate cancer.
Traynor K
Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204
[No Abstract] [Full Text] [Related]
10. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
Sartor O
BJU Int; 2012 Jul; 110(2 Pt 2):E105. PubMed ID: 22176510
[No Abstract] [Full Text] [Related]
11. What Nurses and Patients Need to Know About Sipulecucel-T Immunotherapy for Prostate Cancer.
Becze E
ONS Connect; 2015 Jun; 30(2):40-1. PubMed ID: 26146750
[No Abstract] [Full Text] [Related]
12. Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product.
Baghdadi R
Oncology (Williston Park); 2010 Sep; 24(10):881-3. PubMed ID: 21138168
[No Abstract] [Full Text] [Related]
13. Managed care considerations. A new era of advanced prostate cancer management.
Muller R
Manag Care; 2011 Sep; 20(9 Suppl 5):5. PubMed ID: 22043721
[No Abstract] [Full Text] [Related]
14. The landmark approval of Provenge, what it means to immunology and "in this issue": the complex relation between vaccines and autoimmunity.
Bot A
Int Rev Immunol; 2010 Jun; 29(3):235-8. PubMed ID: 20521923
[No Abstract] [Full Text] [Related]
15. Immune-boosting prostate cancer vaccine endorsed by FDA advisors.
McBride D
ONS Connect; 2007 Jul; 22(7):19. PubMed ID: 17694780
[No Abstract] [Full Text] [Related]
16. Listening to Provenge--what a costly cancer treatment says about future Medicare policy.
Chambers JD; Neumann PJ
N Engl J Med; 2011 May; 364(18):1687-9. PubMed ID: 21470004
[No Abstract] [Full Text] [Related]
17. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
Drake CG
J Natl Cancer Inst; 2012 Sep; 104(18):1422; author reply 1422-3. PubMed ID: 22911668
[No Abstract] [Full Text] [Related]
18. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
Kantoff PW; Higano CS; Small EJ; Whitmore JB; Frohlich MW; Schellhammer PF
J Natl Cancer Inst; 2012 Jul; 104(14):1107-9; author reply 1109-12. PubMed ID: 22825556
[No Abstract] [Full Text] [Related]
19. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
Gulley JL; Leitman SF; Dahut W; Schlom J
J Natl Cancer Inst; 2012 Jul; 104(14):1106; author reply 1109-12. PubMed ID: 22825555
[No Abstract] [Full Text] [Related]
20. [Sipuleucel-T: a prostate cancer vaccine: "instructions for use" for urologists].
Ouzaid I; Ravery V
Prog Urol; 2011 Oct; 21(9):595-8. PubMed ID: 21943654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
